Amrize (NYSE:AMRZ) Stock Bumped Down to Hold by Berenberg Bank

Amrize (NYSE:AMRZ) was downgraded by equities research analysts at Berenberg Bank from a “buy” rating to a “hold” rating in a research report issued on Monday, FinViz reports. They presently have a $46.00 price target on the stock, down from their previous price target of $48.00. Berenberg Bank‘s target price suggests a potential upside of 9.79% from the stock’s current price.

A number of other brokerages have also commented on AMRZ. DA Davidson upped their price objective on Amrize from $40.00 to $43.00 and gave the company a “neutral” rating in a report on Friday, October 30th. Sanford C. Bernstein reissued an “outperform” rating and issued a $60.00 target price on shares of Amrize in a research report on Monday, September 21st. Weiss Ratings cut shares of Amrize from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. decreased their price target on shares of Amrize from $52.00 to $48.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 13th. Finally, Barclays lowered their price target on shares of Amrize from $55.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, October 19th. Eight investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $47.65.

Amrize Price Performance

Amrize stock opened at $41.90 on Monday. Amrize has a 12 month low of $35.78 and a 12 month high of $65.94. The stock’s 50 day moving average is $39.53 and its 200-day moving average is $50.30. The company has a current ratio of 1.07, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $23.17 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.64 and a beta of 0.03.

Amrize (NYSE:AMRZ) last announced its earnings results on Wednesday, October 28th. The company reported $1.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.05. The company had revenue of $3.77 billion for the quarter. Amrize had a return on equity of 10.02% and a net margin of 9.93%. Amrize’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $0.98 EPS. Equities research analysts expect that Amrize will post 2.30 EPS for the current year.

Insider Activity

In other news, Director Jacques Sanche bought 4,150 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were purchased at an average cost of $45.02 per share, with a total value of $186,833.00. Following the acquisition, the director directly owned 9,766 shares in the company, valued at $439,665.32. This represents a 73.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jaime Hill bought 1,500 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was purchased at an average cost of $47.12 per share, for a total transaction of $70,680.00. Following the completion of the acquisition, the insider owned 29,698 shares in the company, valued at approximately $1,399,369.76. This trade represents a 5.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 48,983 shares of company stock valued at $2,158,755. Company insiders own 0.54% of the company’s stock.

Institutional Trading of Amrize

Several large investors have recently made changes to their positions in AMRZ. Caldwell Sutter Capital Inc. increased its stake in Amrize by 11.5% in the first quarter. Caldwell Sutter Capital Inc. now owns 2,675 shares of the company’s stock valued at $150,000 after acquiring an additional 275 shares during the last quarter. Grove Bank & Trust lifted its stake in Amrize by 2.1% during the third quarter. Grove Bank & Trust now owns 17,477 shares of the company’s stock worth $653,000 after purchasing an additional 353 shares during the last quarter. Norman Fields Gottscho Capital Management LLC lifted its stake in Amrize by 4.3% during the second quarter. Norman Fields Gottscho Capital Management LLC now owns 11,515 shares of the company’s stock worth $614,000 after purchasing an additional 475 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in Amrize by 3.9% during the third quarter. Farther Finance Advisors LLC now owns 14,506 shares of the company’s stock worth $542,000 after purchasing an additional 543 shares during the last quarter. Finally, Choreo LLC boosted its holdings in shares of Amrize by 4.2% in the 3rd quarter. Choreo LLC now owns 17,713 shares of the company’s stock valued at $662,000 after purchasing an additional 706 shares in the last quarter.

Amrize Company Profile

Amrize is a North American building materials and construction solutions company serving customers across the United States and Canada. Its operations span the construction materials and building envelope markets.

The company supplies cement, aggregates, ready-mix concrete and asphalt, as well as roofing and other building-envelope products and services. These materials and solutions support residential, commercial and infrastructure projects.

Amrize became an independent publicly traded company in 2025 through the spin-off of Holcim’s North American business.